PGI5: HEALTH CARE COST SAVINGS WITH BUDESONIDE CONTROLLED ILEAL RELEASE CAPSULES (CIR) IN CROHN'S DISEASE
| Autor: | K Ericsson, Claes-Henrik Florén, Sixten Borg, Åke Danielsson, Robert Löfberg |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
Budesonide
medicine.medical_specialty Crohn's disease business.industry 030503 health policy & services Health Policy Public Health Environmental and Occupational Health Disease medicine.disease Placebo 3. Good health Surgery Clinical trial 03 medical and health sciences 0302 clinical medicine Maintenance therapy Internal medicine Health care Health care cost Medicine 030212 general & internal medicine 0305 other medical science business medicine.drug |
| Zdroj: | Value in Health. 4:123 |
| ISSN: | 1098-3015 |
| Popis: | BACKGROUND: Economic aspects are important when assessing the overall benefit of a treatment strategy. The number of investigations of these aspects are few within the field of Crohn's disease (CD). OBJECTIVE: To assess the economic consequences, from a health care budget perspective, of treating CD patients with budesonide CIR (Entocort capsules) 6 mg per day as maintenance therapy compared to no maintenance treatment (NMT). METHOD: A validated decision-analytic model (Noble et al., 1998) on the treatment of CD in Sweden was used. The model used pooled patient data from randomised, double blind trials of budesonide CIR capsules (n = 90) versus placebo (n = 90) and covers a study period of one year. For events not investigated in the clinical trials, literature and panel data were used. Cost inputs for health care resources were based on costs observed for 11 regional hospitals in Sweden in year 1996. The analysis took into account costs for health care resources associated with managing inactive and active phases of CD, e.g., diagnostic and surgical procedures, physician visits, hospitalisations and drug consumption. Panel data and cost inputs were tested in a sensitivity analysis. RESULT: Average annual cost per patient was SEK 36,745 for budesonide CIR capsules patients compared to SEK 38,130 for NMT patients. With a Swedish prevalence between 13,000 to 18,000 patients this could mean annual savings of 18 to 25 million SEK (2–2.8 million USD). Stability of the results was confirmed when altering values on panel data and cost inputs. CONCLUSION: Budesonide CIR capsules, prolonging time in remission, is a cost-saving treatment strategy for the treatment of Crohn's disease in Sweden. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect